03 May, 2021 Early Results on Clinical Outcome Measures Presented for OXLUMO® (lumasiran) at ASPN/PAS 2021 Annual Congress
Positive early results on clinical outcome measures from the 12-month analysis of ILLUMINATE-A Phase 3 study of OXLUMO® (lumasiran), an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – for the treatment of primary hyperoxaluria type 1 (PH1), were presented at the American Society of Pediatric Nephrology (ASPN)/Pediatric Academic Societies (PAS) virtual meeting held on April 30–May 4, 2021. The results showed that treatment with OXLUMO for 12 months was associated with evidence of improvements in nephrocalcinosis in one or both kidneys of PH1 patients, relative to baseline. Additional data were also presented regarding effects on estimated glomerulal filtration rate (eGFR) and kidney stone events.
Read our press release
Sas, et al. “Clinical outcomes in Phase 3 studies of lumasiran in pediatric and adult patients with primary hyperoxaluria type 1”
